发明授权
- 专利标题： Antibodies against human angiopoietin 2
- 专利标题（中）： 抗人血管生成素抗体2
-
申请号： US13693085申请日： 2012-12-04
-
公开(公告)号： US09340609B2公开(公告)日： 2016-05-17
- 发明人: Ulrich Brinkmann , Remko Albert Griep , Klaus Kaluza , Anita Kavlie , Christian Klein , Joerg Thomas Regula , Werner Scheuer
- 申请人： Hoffmann-La Roche Inc.
- 申请人地址： US NJ Little Falls
- 专利权人： Hoffmann-La Roche Inc.
- 当前专利权人： Hoffmann-La Roche Inc.
- 当前专利权人地址： US NJ Little Falls
- 优先权： EP08021835 20081216
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; C07K16/22 ; C12N15/85
摘要：
The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6. The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6.
公开/授权文献
- US20130156789A1 ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 公开/授权日：2013-06-20
信息查询
